MX2022009778A - Polimorfos de elafibranor. - Google Patents
Polimorfos de elafibranor.Info
- Publication number
- MX2022009778A MX2022009778A MX2022009778A MX2022009778A MX2022009778A MX 2022009778 A MX2022009778 A MX 2022009778A MX 2022009778 A MX2022009778 A MX 2022009778A MX 2022009778 A MX2022009778 A MX 2022009778A MX 2022009778 A MX2022009778 A MX 2022009778A
- Authority
- MX
- Mexico
- Prior art keywords
- elafibranor
- polymorphs
- relates
- present
- crystalline forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a formas cristalinas novedosas de elafibranor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2020053359 | 2020-02-10 | ||
| PCT/EP2021/052713 WO2021160520A1 (en) | 2020-02-10 | 2021-02-04 | Polymorphs of elafibranor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009778A true MX2022009778A (es) | 2022-09-09 |
Family
ID=69591622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009778A MX2022009778A (es) | 2020-02-10 | 2021-02-04 | Polimorfos de elafibranor. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230094109A1 (es) |
| EP (1) | EP4103546A1 (es) |
| JP (2) | JP2023513712A (es) |
| KR (1) | KR20220140760A (es) |
| CN (1) | CN115003653A (es) |
| AU (1) | AU2021219286A1 (es) |
| BR (1) | BR112022015807A2 (es) |
| CA (1) | CA3163583A1 (es) |
| IL (1) | IL294503A (es) |
| MX (1) | MX2022009778A (es) |
| WO (1) | WO2021160520A1 (es) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2841900B1 (fr) * | 2002-07-08 | 2007-03-02 | Genfit S A | Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations |
| FR2841784B1 (fr) | 2002-07-08 | 2007-03-02 | Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations | |
| AU2010323066B2 (en) | 2009-11-26 | 2014-12-11 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
| PT2571843T (pt) * | 2010-05-17 | 2018-01-29 | Genfit | Preparação melhorada de derivados de calcona |
| CA2897258C (en) | 2013-01-18 | 2021-02-02 | Genfit | Methods of treatment of fibrosis and cancers |
| WO2017167935A1 (en) * | 2016-03-31 | 2017-10-05 | Genfit | Methods of treatment of cholestatic diseases |
| CA3051146A1 (en) * | 2017-01-22 | 2018-07-26 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of gft-505 and preparation method and use thereof |
| WO2019099761A1 (en) * | 2017-11-16 | 2019-05-23 | Teva Pharmaceuticals International Gmbh | Solid state forms of elafibranor |
| WO2019186410A1 (en) * | 2018-03-27 | 2019-10-03 | Lupin Limited | Solid forms of elafibranor and processes thereof |
| WO2020039297A1 (en) * | 2018-08-24 | 2020-02-27 | Mankind Pharma Ltd. | Novel compounds and their use in preparation of elafibranor and pharmaceutical acceptable salts thereof |
-
2021
- 2021-02-04 EP EP21704454.4A patent/EP4103546A1/en active Pending
- 2021-02-04 IL IL294503A patent/IL294503A/en unknown
- 2021-02-04 AU AU2021219286A patent/AU2021219286A1/en active Pending
- 2021-02-04 MX MX2022009778A patent/MX2022009778A/es unknown
- 2021-02-04 JP JP2022548762A patent/JP2023513712A/ja active Pending
- 2021-02-04 US US17/798,484 patent/US20230094109A1/en active Pending
- 2021-02-04 CA CA3163583A patent/CA3163583A1/en active Pending
- 2021-02-04 WO PCT/EP2021/052713 patent/WO2021160520A1/en not_active Ceased
- 2021-02-04 BR BR112022015807A patent/BR112022015807A2/pt unknown
- 2021-02-04 KR KR1020227029839A patent/KR20220140760A/ko active Pending
- 2021-02-04 CN CN202180011258.XA patent/CN115003653A/zh active Pending
-
2025
- 2025-07-04 JP JP2025113890A patent/JP2025146849A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021160520A1 (en) | 2021-08-19 |
| JP2025146849A (ja) | 2025-10-03 |
| IL294503A (en) | 2022-09-01 |
| AU2021219286A1 (en) | 2022-09-22 |
| JP2023513712A (ja) | 2023-04-03 |
| KR20220140760A (ko) | 2022-10-18 |
| CN115003653A (zh) | 2022-09-02 |
| EP4103546A1 (en) | 2022-12-21 |
| US20230094109A1 (en) | 2023-03-30 |
| BR112022015807A2 (pt) | 2023-03-14 |
| CA3163583A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090917A1 (ru) | Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение | |
| ECSP21088515A (es) | Compuestos de pirrolidina | |
| CO2019010035A2 (es) | Síntesis de inhibidor de mcl-1 | |
| PE20210549A1 (es) | Derivado de amino-metil piperidina como inhibidor de quinasa | |
| MX2019011496A (es) | Composiciones de niraparib. | |
| AR116790A1 (es) | PROCEDIMIENTO PARA LA PREPARACIÓN DE 3a-HIDROXI-5a-PREGNAN-20-ONA (BREXANOLONA) | |
| MX2019014907A (es) | Sintesis de derivados de fosfato. | |
| EA201891769A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЯ ПИРРОЛО[3,2-d]ПИРИМИДИНА И ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ | |
| MX2021007141A (es) | Sintesis de gamma-carbolinas fusionadas con heterociclo sustituido. | |
| CL2023001049A1 (es) | Procedimiento para la fabricación de compuestos orgánicos | |
| MX2020009843A (es) | Formas cristalinas y metodos de produccion de formas cristalinas de un compuesto. | |
| EA202090980A1 (ru) | Синтез антибактериальных аминогликозидных аналогов | |
| EA202190475A1 (ru) | Мини-gde для лечения гликогеноза iii типа | |
| CL2020000376A1 (es) | Compuesto pentacíclico. | |
| CL2024003023A1 (es) | Inhibidores lrrk2. | |
| BR112023020658A2 (pt) | Síntese de compostos análogos à rapamicina | |
| EP4165001A4 (en) | PRODUCTION OF POTASSIUM PHOSPHATES | |
| CL2021000902A1 (es) | Método para la fabricación de gemas sintéticas. | |
| EP4509179A3 (en) | Polymorphs | |
| CL2023001137A1 (es) | Procedimiento para la purificación de pleuromutilinas | |
| MX2022009778A (es) | Polimorfos de elafibranor. | |
| MX2021000334A (es) | Nuevas formas polimorficas de ciclo (-his-pro). | |
| MX2020004050A (es) | Intermediario cristalino de linagliptina y proceso para la preparacion de linagliptina. | |
| ECSP21089373A (es) | Intermedios espirobicíclicos novedosos | |
| CL2021001458A1 (es) | 3ß-(benciloxi)-17a-metil-pregn-5-en-20-ona para uso en el tratamiento de trastornos cognitivos. |